Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T12:55:30.343Z.
Calculation as of: 2026-10-06T12:55:30.343Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ce14650c18fa49a41504767bbd6ec089d5034b69e4d808542ce8aeb5b63776d1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
ALX Oncology Holdings Inc.
Market Cap
$162.82M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$160.82M
Operating Cash Flow Yield
N/A
TTM Avg
2.00%
3Y Avg
1.62%
5Y Avg
3.25%
Market Cap
$153.84M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$172.99M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.04M
Operating Cash Flow Yield
N/A
TTM Avg
0.52%
3Y Avg
0.52%
5Y Avg
7.75%
Market Cap
$152.45M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$152.16M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$174.17M
Operating Cash Flow Yield
N/A
TTM Avg
0.62%
3Y Avg
0.62%
5Y Avg
0.62%
Market Cap
$149.51M
Operating Cash Flow Yield
N/A
TTM Avg
4.20%
3Y Avg
4.20%
5Y Avg
4.20%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. (ALXO) | $162.82M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $160.82M | N/A | 2.00% | 1.62% | 3.25% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $172.99M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $173.04M | N/A | 0.52% | 0.52% | 7.75% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $174.17M | N/A | 0.62% | 0.62% | 0.62% |
| Codexis, Inc. (CDXS)vs › | $149.51M | N/A | 4.20% | 4.20% | 4.20% |
| Cue Biopharma, Inc. (CUE)vs › | $176.96M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
